Table 5.
Abnormal interpretation for 64,244 screening mammographic examinations and 13,706 diagnostic mammographic examinations with registry outcomes.
| MEASUREMENT AND DATA | SCREENING EXAMINATIONS | SCREENING GUIDELINES15 | DIAGNOSTIC EXAMINATIONS | DIAGNOSTIC GUIDELINES15 |
|---|---|---|---|---|
| Recall rate (%) | 7.7 | 5–12 | 13.77 | 9–25 |
| No. of abnormality interpretations* | 4937 | 1888 | ||
| Total no. of examinations | 64,244 | 13,706 | ||
| PPV1, abnormal interpretations (%) | 6.7 | 3–8 | NA | |
| No. of cancers | 329 | NA | ||
| No. of abnormal interpretation* | 4937 | NA | ||
| PPV2, biopsy recommended (%) | 26.0 | 20–40 | 30.8 | 20–45 |
| No. of cancers | 258 | 581 | ||
| No. of abnormal interpretation+ | 994 | 1888 | ||
| PPV3, performed (%) | 29.4 | NA | 35.0 | 25–50 |
| No. of cancers | 229 | 513 | ||
| No. of abnormal interpretation++ | 778 | 1464 | ||
| Cancer detection rate (per 1000) | 5.9 | > = 2.5 | 49.7 | > = 30 |
| No. of cancers | 381 | 681 | ||
| Total no. of examinations | 64,244 | 13,706 |
Notes:
*
An abnormal interpretation was based on assignment of BI-RADS Category 0, 4, or 5 for screening examinations, BI-RADS Category 4 or 5 for diagnostic examinations.
+
A classification of biopsy recommendation was based on the assignment of BI-RADS Category 4 or 5 at the final assignment.
++
A classification of biopsy recommendation and performed was based on the assignment of BI-RADS Category 4 or 5 at the final assignment.